In recent years, new molecular targeted therapies have been developed, including ibrutinib, a Btk inhibitor, which has changed the management and clinical history of patients with multi-treated CLL, or with a very poor prognostication [30,31,32]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.